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Abstract
Background: Despite of intense research in early cancer detection, there is a lack of biomarkers for the reliable detection of
malignant tumors, including non-small cell lung cancer (NSCLC). DNA methylation changes are common and relatively
stable in various types of cancers, and may be used as diagnostic or prognostic biomarkers.
Methods: We performed DNA methylation profiling of samples from 48 patients with stage I NSCLC and 18 matching
cancer-free lung samples using microarrays that cover the promoter regions of more than 14,500 genes. We correlated DNA
methylation changes with gene expression levels and performed survival analysis.
Results: We observed hypermethylation of 496 CpGs in 379 genes and hypomethylation of 373 CpGs in 335 genes in
NSCLC. Compared to adenocarcinoma samples, squamous cell carcinoma samples had 263 CpGs in 223 hypermethylated
genes and 513 CpGs in 436 hypomethylated genes. 378 of 869 (43.5%) CpG sites discriminating the NSCLC and control
samples showed an inverse correlation between CpG site methylation and gene expression levels. As a result of a survival
analysis, we found 10 CpGs in 10 genes, in which the methylation level differs in different survival groups.
Conclusions: We have identified a set of genes with altered methylation in NSCLC and found that a minority of them
showed an inverse correlation with gene expression levels. We also found a set of genes that associated with the survival of
the patients. These newly-identified marker candidates for the molecular screening of NSCLC will need further analysis in
order to determine their clinical utility.
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Introduction
Lung cancer is the leading cause of cancer-related deaths in the
world. Epigenetic events are early and frequent in carcinogenesis
[1,2,3], which makes DNA methylation an attractive biomarker
for cancer. Epigenetic events could also provide a tractable link
between the genome and the environment, with the epigenome
serving as a biochemical record of relevant life events, e.g.
cigarette smoking [4].
Lung cancer is morphologically divided into non-small cell and
small cell lung cancer (NSCLC and SCLC). NSCLC accounts for
about 80% of the lung cancers and is a heterogeneous clinical
entity with major histological subtypes such as squamous cell
carcinoma (SCC), adenocarcinoma (AC) and large cell carcinoma
[5]. A common feature of the different subtypes of NSCLC is the
somewhat slower growth and spread compared to SCLC, enabling
surgical eradication in its early stages. Only a minor fraction of
NSCLC cases are currently diagnosed in clinical stages I to IIb,
where surgical removal is the therapy of choice.
The biomarker-driven approach at preinvasive phases could aid
in diagnosing or ruling out lung cancer. Current markers,
including squamous cell carcinoma antigen, carcinoembryonic
antigen, cytokeratin 19 fragment antigen 21-1 and neuron-specific
enolase were shown to lack satisfactory diagnostic power. In
a recent study, only 37.3% of early-stage lung cancers could be
diagnosed using the combination assays of the above-mentioned
tumor markers [6].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39813Our study was aimed at the genome-wide identification of DNA
methylation-based biomarker candidates in early-stage NSCLC.
DNA methylation occurs vastly in the context of cytosine-guanine
dinucleotides (CpGs) [7]. CpG-rich short stretches (CpG islands)
are usually located in the promoter region of genes and are
normally kept in the demethylated state [8]. In cancer, CpG
islands located in the promoter area of tumor suppressor genes and
‘‘house-keeping’’ genes become hypermethylated, which can lead
to decreased expression of these genes. At the same time, the
genome is globally demethylated, which in turn can lead to the
activation of oncogenes [9,10]. Methylation of CpG island shores
– regions with lower CpG density within approximately 2 kb of
CpG islands - is also closely associated with transcriptional
inactivation [11].
Recently, significant progress has been made in the genome-
wide DNA methylation analysis. The methods include bisulfite
conversion of DNA, immunoprecipitation or affinity purification
of methylated DNA followed by microarray analysis or high-
throughput sequencing [12]. It has been shown that in terms of
accuracy, bisulfite-based methods perform slightly better than
enrichment-based methods and do not require a statistical
correction for CpG bias [13].
We have performed a genome-wide DNA methylation study of
stage I NSCLC to obtain an insight into early-stage epigenetic
alterations in lung cancer and identify potential diagnostic or
prognostic biomarkers. In our study we used the HumanMethyla-
tion27 BeadChips (Illumina, Inc) that enable cost-effective
quantitative comparisons across many samples.
Results
CpG Methylation Analysis
Overall, we detected 496 CpGs in 379 genes hypermethylated
and 373 CpGs in 336 genes hypomethylated in NSCLC (Figure
S1, Table S1). A heatmap of the 100 most differently methylated
genes in NSCLC compared to control samples is shown in
Figure 1.
Compared to AC samples, SCC samples had 263 CpGs in 223
hypermethylated genes and 513 CpGs in 436 hypomethylated
genes (Figure S2, Table S2).
Two DNA samples (IDs 33 and 107) were processed in
duplicate as an internal control of the assay’s reproducibility.
Pearson’s correlation coefficient for both duplicates was 0.998.
Methylation levels determined by the Infinium assay were
validated using Sanger sequencing of bisulfite-converted DNA
for 11 CpGs (six CpGs from NSCLC versus control samples
analysis and five CpGs from survival analysis). The mean
correlation between two methods was 83% (range 48.9%;
97.4%) (Figure S3).
The CpG sites analyzed by HumanMethylation27 assay are
located within 1.5 kb upstream to 1 kb downstream of the TSS of
their respective genes. We found a significant difference in the
location of hypermethylated vs. hypomethylated CpGs relative to
the closest TSS (p=0.0001, Welch Two Sample t-test). Hyper-
methylated CpGs were preferentially located at TSSs, 39
downstream of the TSS or in CpG islands. In contrast,
hypomethylated CpGs were frequently found 59 upstream of the
respective TSSs or in CpG island shores [11] (Table 1, Figure 2).
Different CpGs of HSPA12B, PABPC5 and TP73 were either
hyper- or hypomethylated in NSCLC. In the TP73 gene, the
hypermethylated CpG site in the tumor sample was located
upstream of the TSS of the full-length mRNA isoform.
Hypomethylated TP73 CpGs were located close to the TSSs of
the shorter isoforms. Hypermethylated CpGs of the HSPA12B and
PABPC5 were located in their 59 CpG islands, whereas
hypomethylated CpGs were located upstream, outside the CpG
islands.
Gene Expression Microarray Validation by qRT-PCR
Gene expression array setup and results are reported in the
recent paper [14]. 10 genes and eight sample pairs were used to
validate microarray results, using qRT-PCR technology. All the
genes showed the same direction of over- or underexpression in
the lung cancer samples, using both technologies (Figure 3). Seven
genes showed a significant correlation between the expression fold-
changes determined by qRT-PCR and microarray (p,0.05, R
.0.7) (Figure S4).
Methylation related to Gene Expression Changes
Using Pearson’s correlation analysis, we were able to determine
the expected inverse correlation between the differential methyl-
ation levels and gene expression values for 378 (43.5%) of the 869
differentially methylated CpGs between NSCLC and control
samples. In different histological groups we were able to find 337
of 780 CpGs (43.2%), the methylation levels of which were
inversely correlated to the gene expression levels.
We performed a qPCR analysis of the different TP73 isoforms
to test whether differential methylation next to the TSSs of
different isoforms affects their expression level. The qPCR analysis
did not reveal a statistically significant difference (p-value 0.36,
paired t-test) between the expression levels of the two isoforms in
our tumor samples.
Ingenuity Pathway Analysis
We performed in silico functional and interaction analyses of the
differentially methylated genes using Ingenuity Pathway Analysis
(IPA) software (Ingenuity Systems, Redwood City, CA), and found
78 network eligible genes and 451 Functions/Pathways eligible
genes. By including the known direct and indirect interactions, the
most prominently represented gene network was related to tumor
necrosis factor (TNF, Figure S5). Most of the genes (n=22) in the
network were hypomethylated, but some genes (n=7) were also
hypermethylated.
DNA Methylation related to Smoking Behavior
Based on tobacco smoking pack-years data, we asked whether
smoking affects the DNA methylation patterns in a tumor. One
patient who lacked smoking data was excluded. Linear regression
analysis was performed using the Bioconductor Limma package.
Analysis within tumor samples did not show any differentially
methylated genes related to the extent of tobacco smoking.
Comparing the limited number of non-smokers (n=3, 6.4%) with
smokers (n=44, 93.6%) we found four differentially methylated
CpG-sites in three genes (p,0.05, FDR adjusted), which are all
hypomethylated in smokers group: CXorf38, MTHFD2 and TLL2.
Altered Methylation and Long-term Survival
We performed two types of survival analyses to find potential
prognostic methylation markers. The patients with only up to one
month survival after surgery (n=2) were excluded to avoid any
potential confounding influence of postoperative complications.
Firstly, we performed a Kaplan-Meier survival analysis on each
of the CpG sites by dividing the Beta values into low, medium and
high methylation groups. We only report results where all groups
were larger than five patients. As a result, we found 10 CpGs in 10
genes, with methylation level differences in different survival
groups (Figure 4). Patients with a medium methylation level of
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survival than patients with high-level methylation. Patients with
a medium methylation level of CLEC11A and GRIK3 had better
survival compared to low-level methylation. Patients with a low
methylation level of CYP1A1 and INGX had better survival than
those with medium-level methylation. Patients with a high
methylation level for PIK3R5 had better survival than those with
medium-level methylation.
Secondly, we performed the differential methylation analysis by
combining Cox proportional hazard analysis and Wilcoxon rank-
sum test. We found 18 CpGs in 15 genes in patients with 1 to 24
months survival (n=12) vs. patients with 60 months and longer
survival (n=15), p,0.05, and the methylation difference cut-off
applied. From the differentially methylated genes, DXS9879E
(LAGE3), RTEL1 and MTM1 were hypermethylated, and
SCUBE3, SYT2, KCNC3, KCNC4, GRIK3, CRB1, SOCS2, ACTA1,
Figure 1. Differential DNA methylation between NSCLC and normal lung samples. DNA methylation levels are shown for the top 100 CpG
sites with the highest delta Beta values (FDR corrected) of DNA methylation between cancer tissue and normal lung tissue. Methylation Beta-values
are represented as row Z-scores. A heatmap was generated using unsupervised 2D hierarchical cluster analysis. Red indicates high methylation and
blue indicates low methylation relative to the row mean.
doi:10.1371/journal.pone.0039813.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39813Figure 2. CpGs’ distance from TSS. We measured CpGs’ distance from the transcription start site (TSS). a) Distance from TSS of all the CpGs on the
methylation array. b) Distance from TSS of hypermethylated CpGs (dotted line) and distance from TSS of hypomethylated CpGs (continuous line). On
the x-axis, the distance from TSS is measured in bp-s, and on the y-axis N represents the number of CpGs.
doi:10.1371/journal.pone.0039813.g002
Table 1. Distance of differentially methylated CpGs to the nearby transcription start sites (TSS, FDR corrected p,0.05, mean
difference in methylation level in NSCLC vs tumor-free lung at least 13.6%).
Hypermethylated CpGs Hypomethylated CpGs
Distance to TSS (median; 1
st quartile; 3
rd quartile) 20.0; 2215; 229 263; 2469.2; 132.5
Located inside CpG island 86% (429) 23% (86)
Located outside CpG island 14% (67) 77% (287)
Distance to TSS of hyper- vs hypomethylated CpGs differed by p=0.0001 (Welch Two Sample t-test).
doi:10.1371/journal.pone.0039813.t001
Methylation Markers of Non-Small Cell Lung Cancer
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39813ZNF660, MDFI, ALDH1A3 and SRD5A2 were hypomethylated in
the group with poor survival (Figure S6).
Discussion
We have performed a genome-wide DNA methylation study in
48 stage I NSCLC patients and 18 macroscopically cancer-free
control samples by using cluster analysis to search for genes that
distinguish between the cancerous and normal lung tissue and
compared these genes’ methylation levels with their expression
levels. In addition, we performed in silico functional and interaction
analysis of differently methylated genes using IPA software. Linear
regression was used to find genes related to smoking, and Kaplan-
Meier survival analysis was performed to identify the differential
methylation of genes related to patient survival.
As a result, we detected 496 CpGs in 379 hypermethylated
genes and 373 CpGs in 336 genes that were hypomethylated in
NSCLC. A perfect separation of the control lung tissue samples
from NSCLC samples was not obtained, as one normal lung
sample clustered together with the cancer samples and six cancer
samples (one in replicate) showed methylation patterns somewhat
resembling the tumor-free lung tissue. Since we used non-dissected
Figure 3. The concordance between microarray and qRT-PCR measurements. On the y-axis is shown average log2fold-change determined
by Illumina array and qRT-PCR (8 sample pairs). Error bars indicate standard error of the mean (SEM).
doi:10.1371/journal.pone.0039813.g003
Figure 4. Survival curves of 10 differentially methylated CpG sites. We performed a survival test on each of the CpG sites. The methylation
values are divided into 3 groups: low (0–0.25), medium (0.25–0.75) and high (0.75–1). As a result we found 10 CpG sites whose methylation level
differs in different survival groups. The x-axis shows survival in years and the y-axis shows overall survival.
doi:10.1371/journal.pone.0039813.g004
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confounding effect of non-neoplastic tissue present in these
samples. Pathological examination of the NSCLC samples with
DNA methylation profiles similar to the normal lung samples
revealed either low tumor content (10 to 30%) or a very
heterogeneous composition of tumor cells in the samples. These
co-clustering cancer samples and cancer-free lung samples were
therefore excluded from further analyses.
Our first goal was to identify the genes involved in early events
in tumor-specific methylation. As a result, our screening un-
covered some well-known methylation markers, some of which
have tumor suppressor activity: CDKN2A, MGMT, GATA4,
HOXA7, HOXA9, RUNX3, SFRP1. Most of the identified genes
are novel methylation markers for NSCLC, although some of
these have been described as methylated in other cancers.
LGALS12 is a candidate tumor suppressor that is able to arrest
the cell cycle and inhibit the proliferation of several cancer cell
lines [15]. In breast cancer, LGALS12 has been found down-
regulated in the malignant tissue [16].
The second goal of our study was to correlate the methylation
level changes with the gene expression data. Using Pearson’s
analysis, we were able to find the expected inverse correlation
between the methylation levels and gene expression values for 378
of 869 CpG sites (43.5%). The highest inverse correlation values
between hypermethylated CpGs and expression values were found
for the AGER (20.78), EPOR (20.65) and AQP1 (20.63) genes.
The mean distance of TSS of inversely correlated genes was
265 bp (range 21498; 917 bp) compared to 2158 bp (range -
1474; 818 bp) of positively correlated CpGs (p-value 0.02, students
t-test). The range of CpGs is probably affected by the fact that
Illumina’s Infinium HumanMethylation27 microarray covers
CpGs that are located predominantly in the vicinity of promoter
regions and not in the gene body or 39UTR. Aquaporin 1 (AQP1)
has been reported to be hypermethylated and downregulated in
NSCLC [17]. AGER, which encodes a receptor of the immuno-
globulin superfamily, has been reported to be downregulated in
NSCLC [18]. The highest inverse correlation values for
hypomethylated CpG sites and expression values were found for
MB (20.63), ADA (20.60) and MAGEA6 (20.60) genes. Myoglo-
bin (MB) is associated with tumor progression and helps to
overcome hypoxia in cancer cells [19]. Hypermethylation and/or
the downregulation of some of the genes identified in our study
(e.g. ALDH1A2, HOXA5, MT1E, SOX17) have been reported in
other cancers [20,21,22,23], but not yet in lung cancer. It is
hypothesised that RASSF1 acts as a tumor suppressor in lung
cancer progression [24]. Among the hypomethylated and
upregulated genes, the most frequently reported gene was
SERPINB5 (Maspin). Overexpression of SERPINB5 has been
associated with cancer progression and a poor prognosis in lung
cancer [25].
We can assume that genes with an inverse correlation have
a higher likelihood of being regulated by methylation. However,
many genes probably become methylated randomly during
carcinogenesis, and this does not necessarily have a steady state
effect on gene expression levels.
In the case of different histology groups, we were able to find an
inverse correlation between the differentially methylated CpG sites
and gene expression values for 337 of 780 CpG sites (43.2%). The
highest inverse correlation values were for ACOX2 (20.75), ARSE
(20.70) and SLC39A4 (20.68), which have not been associated
with NSCLC histological subtypes before. Of the inversely
correlated genes, it has been reported that PIGR, MUC1 and
FOLR1 are downregulated in SCC compared to AC [26,27,28],
which is consistent with our results.
Analysis using IPA software revealed that the dominant
functions of the differentially methylated genes were cell-to-cell
signaling and interaction, DNA replication and repair, cellular
growth and proliferation, cell death, cancer, inflammatory re-
sponse, etc. A number of gene functions, such as cell growth,
proliferation and cell death, are directly involved in cancer
progression, but the immune system also plays an important role
in fighting cancerous cells. It is also widely known that deficiencies
in pathways of DNA repair and damage control are responsible for
most or even all human cancers. After including the known
indirect relations, the most prominent gene network revealed was
related to TNF (Figure S5). TNF has a dual role in tumor biology.
It is a cytokine with well-known anticancer properties, but may
also promote cancer development and progression [29]. Hypo-
methylated genes in the TNF network were cytokines (CCL3,
CCL4, CCL7, CCL8, CCL22, IL21, IL17A, EBI3) that can either
stimulate or inhibit tumor growth and progression. The TNF
network also includes the well-known potent antiapoptotic gene
BCL2, which was also mostly hypomethylated in our NSCLC
samples. ALDH1A3 (aldehyde dehydrogenase 1 family, member
A3) indirectly regulated by TNF plays a role in the detoxification of
aldehydes generated by alcohol metabolism and lipid peroxida-
tion. Hypomethylation of this gene was related to a worse
prognosis in our study cohort (Figure S6).
We found that TP73 had three differentially methylated CpGs,
two of which were hypomethylated in the tumor tissues and
located near the TSS of its shorter isoforms. The hypermethylated
CpG was located upstream of the TSS of the full-length mRNA
isoform. We measured the expression of different isoforms using
qPCR analysis, but did not find any statistically significant
differences (p-value 0.36, paired t-test) in the tumor samples,
although the long isoform was expressed at a slightly lower level
than the short isoform. We performed a Kaplan-Meier survival
test for CpG sites, for which we divided their methylation values
into 3 groups: low (0–0.25), medium (0.25–0.75) and high (0.75–1).
As a result, we found 10 CpGs in 10 genes whose methylation
level differs in different survival groups (Figure 4). UGT1A7 is an
enzyme involved in the metabolism of (pre)carcinogens present in
tobacco smoke. Precarcinogens and their metabolites are consid-
ered to play an important role in the carcinogenesis of the tobacco
smoke-related cancers [30]. It has been shown that polymorphisms
in the UGT1A7 gene are associated with lung cancer, suggesting
that these polymorphisms reduce enzymatic activity [31]. A high
methylation level could also affect UGT1A7 activity and cause
a poor prognosis for NSCLC patients. CYP1A1 (belonging to
cytochrome P450 superfamily) catalyzes many reactions involved
in drug metabolism, also the conversion of polycyclic aromatic
hydrocarbons into reactive metabolites and detoxifications of
environmental carcinogens. It has been shown that CYP1A1 is
hypermethylated in lung cancer samples compared to normal lung
samples, and this was associated with reduced mRNA levels [32].
In our study, higher methylation levels were associated with poor
survival of lung cancer patients that supports the hypothesis that
CYP1A1 may have protective role in cancer progression. Other
genes found in survival analysis have not been reporter to be
involved in lung cancer patients’ survival.
Using a different type of survival analysis, where the differential
methylation analysis was performed by combining Cox pro-
portional hazard analysis and the Wilcoxon rank-sum test, we
were able to analyze 12 patients with a survival of less than 24
months and 15 patients who survived 60 months or more after
surgery. This analysis of the different survival groups revealed 15
differentially methylated genes. RTEL1, the regulator of telomere
elongation helicase 1, seems to be the most functionally interesting
Methylation Markers of Non-Small Cell Lung Cancer
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suppress inappropriate homologous recombination, thereby play-
ing a central role in DNA repair and in the maintenance of
genomic stability. RTEL1 was found to be hypermethylated in our
poor survival group.
Comparing non-smokers (n=3, 6.4%) with smokers (n=44,
93.6%), four differentially methylated CpG-sites related to three
genes, hypermethylated in the non-smokers group were found:
CXorf38, MTHFD2 and TLL2. Missing statistically significant
difference in methylation levels between the different levels of
tobacco smoking could indicate a poor reliability of the pack-years’
data obtained. MTHFD2 has been shown to have a higher
expression in smokers, favouring rapid cell growth. [33]. TLL2 is
a zinc-dependent metalloprotease. Expression of metalloprotei-
nases is required for cell transformation, and this correlates with
tumor progression [34].
By comparing genome-wide changes in the DNA methylation of
normal and lung cancer cells, we were able to gain insight into the
complexity of the methylation program required for cells to
become fully malignant. As a result, we found a panel of genes that
distinguish NSCLC cells from adjacent normal lung cells and also
squamous cell carcinoma from adenocarcinoma. The analysis
revealed a set of differentially methylated CpG sites that appear to
regulate gene expression and another set that had affected the
survival of the patients. These newly-identified methylation
markers are candidates for the further molecular screening of
NSCLC. In order to confirm these markers of NSCLC
carcinogenesis, additional studies and validations are needed.
From the results of our work and from previous findings, we can
assume that altered DNA methylation is an early event in NSCLC.
Materials and Methods
Ethics Statement
The Ethics Committee of Human Studies, University of Tartu,
has approved the study and a written consent was obtained from
the study subjects.
Samples
We analyzed Union for International Cancer Control (UICC)
stage I NSCLC samples [35] from 48 patients and macroscopically
cancer-free ‘‘normal’’ lung control samples from 18 patients. All
the specimens had been isolated during lung surgery at Tartu
University Hospital, Estonia. The patients with adenocarcinoma
(n=6, 12.5%) and its subtype bronchioloalveolar carcinoma
(n=10, 20.8%) were analyzed as one group (n=16, 33.3%).
The remaining 32 (66.7%) of the analyzed patients had squamous
cell carcinoma. The age range in the study group was 41–80 years
(mean age in males n=40, 66.2 years and in females n=8, 65.5
years) (Table S3). The patients did not undergo any preoperative
chemo- or radiotherapy.
At surgery, tissue specimens of appropriate size (1–2 cm
3) were
cut from tumorous and morphologically tumor-free lung tissue.
One half of each sample was fixed in formalin and used for
pathological examination. The other half of each specimen was
snap frozen and stored at 280uC until use. Control samples were
obtained at a site distant from the removed tumor and confirmed
to be tumor-free by the same pathologist.
DNA Extraction and Bisulfite Modification
DNA was extracted from 50 mg of tumor and matching tumor-
free lung tissue with the DneasyH Blood & Tissue kit (Qiagen
GmbH., Hilden, Germany) and with the NucleospinH Tissue kit
(Macherey-Nagel GmbH., Du ¨ren, Germany). DNA yield and
purity were determined using the NanoDropH ND1000 spectro-
photometer (Thermo Fisher Scientific Inc., Waltham, MA). From
each sample, 500 ng of genomic DNA was bisulfite modified using
the EZ DNA Methylation
TM Kit (Zymo Research, Orange, CA)
according to the manufacturer’s recommendations.
Methylation Validation by Sanger Sequencing
For methylation chip validation 11 genes were chosen, five of
these were genes from survival analysis and the remaining six were
genes that distinguished between cancer and normal tissue
(Primers used in study showed in Table S4). Primers for
bisulfite-treated DNA PCR were designed using MethPrimer
[36]. A 20 ml PCR was carried out in 80 mM Tris-HCl (pH 9,4–
9,5), 20 mM (NH4)2SO4, 0,02% Tween-20 PCR buffer, 3 mM
MgCl2, 1X Betaine, 0.25 mM dNTP mix, 2 units of Hot-start Taq
polymerase, 50 pmol of the forward primer, 50 pmol of the
reverse primer, and 20 ng of bisulfite-treated genomic DNA. PCR
cycling conditions were 95uC 15 min for enzyme activation, 95uC
30 sec, 62uC 45 sec, 72uC 120 sec for 17 cycles, touchdown by
20.5uC for every cycle and 95uC 30 sec, 52uC 30 sec, 72uC
120 sec for 21 cycles. Sequencing was done as a service by the
Core Facility of Estonian Biocenter. We analyzed sequencing
traces with Mutation Surveyor software (Softgenetics, State
College, PA, USA) and R statistical computing software (http://
www.r-project.org/).
RNA Extraction and Gene Expression Analysis
Detailed description of the RNA extraction and gene expression
analysis process is given in the recent paper [14].
10 genes and eight sample pairs (tumor and adjacent normal
sample) were used to validate the microarray data. For quantita-
tive RT-PCR (qPCR), cDNAs were synthesized from 700 ng of
total RNA using the First Strand cDNA Synthesis kit (Fermentas,
Vilnius, Lithuania) and oligo dT primers according to the
manufacturer’s protocol. Triplicate qPCR reactions were per-
formed in 384-well plates using SYBR Green ROX mix (ABGene,
Epsom, UK or Fermentas, Vilnius, Lithuania) and ABI 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA).
Data were analyzed using the SDS 2.2.2 (Applied Biosystems) and
R statistical computing software (http://www.r-project.org/).
The geometric mean expression of two reference genes (ESD
and S18RNA) was used as a reference. Expression fold change
between normal and tumor sample were calculated using 2
-DDCt
method. Pearson correlation analyses were used to assess the
accordance between fold changes identified by qRT-PCR and
array experiments.
In addition, qRT-PCR was used to determine the TP73
expression level. Primers used for the TP73 qPCR amplifications
are listed in Table S5.
DNA Methylation Analysis
Methylation analysis was performed using InfiniumH Human-
Methylation27 RevB BeadChips (Illumina Inc.). The assay covers
27,578 CpGs in 14,495 genes located predominantly in CpG
islands within proximal promoter regions, between 1.5 kb
upstream and 1 kb downstream of the transcription start sites
(TSS). A CpG island in this assay is defined as a nucleotide
sequence of (1) 200 bp or greater in length, (2) 50% or greater in
GC-percent, and (3) 0.60 or greater in the ratio of observed CpG
sites over expected CpG sites in that region [10]. The
HumanMethylation27 beadchips also cover CpG sites in the
regulatory regions of 1,000 well-known cancer genes, 150
differentially methylated genes in various cancers and 110 miRNA
Methylation Markers of Non-Small Cell Lung Cancer
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standard protocols.
We performed cluster analysis of the methylation profiles by
using the Limma program of Bioconductor package in R statistical
computing software (www.bioconductor.org). Prior to analysis we
quantile normalized the methylation data to eliminate systematic
differences between the chips. The analysis was performed using t-
tests with an empirical Bayes’ correction from the Bioconductor
Limma package [37]. The differentially methylated genes were
clustered hierarchically and visualized using a heatmap.
All the methylation differences (differences between the Beta-
values representing the calculated level of methylation from 0 to 1,
alternatively 0% to 100% for each analyzed CpG) were identified
using a false discovery rate (FDR) corrected p,0.05 and $0.136
mean methylation level difference that was previously shown to
detect differences with at least 95% confidence [38]. For Kaplan-
Meier survival analysis, we divided the Beta values into low (0–
0.25), medium (0.25–0.75) and high (0.75–1) methylation group
and performed a log-rank test to assess the difference in survival
between the groups. We corrected these p-values using FDR and
used 0.05 as the significance level.
Methylation Related to Gene Expression Analysis
Within the available data, we calculated Pearson’s correlations
between the CpG site methylation levels and their respective gene
expression levels (Table 2, Table S1 and S2).
We computed the permutation-based p-values by permuting
individuals and recalculating the median gene expression levels
10,000 times. All CpGs and genes represented by both the
methylation and gene expression arrays were included in
permutations. Three genes (AGER, NR0B2, PPP1R14D) yielded
two significant correlations; only the strongest correlations are
shown (Table 2).
Supporting Information
Figure S1 Differential DNA methylation between
NSCLC and normal lung samples. DNA methylation profiles
for 48 NSCLC samples and 18 normal lung samples are shown.
We detected 496 CpGs hyper- and 373 CpGs hypomethylated in
NSCLC. Methylation values (Beta-values) are represented as row
Z-scores for each gene. Heatmap was generated with unsupervised
2D hierarchical cluster analysis. Red indicates high methylation
and blue indicates low methylation relative to the row mean.
(PDF)
Figure S2 Differential DNA methylation between squa-
mous cell carcinoma and adenocarcinoma. DNA methyl-
ation profiles for 16 adenocarcinoma (AC) samples and 32
squamous cell carcinoma (SCC) samples are shown. We detected
263 hypermethylated CpG sites and 513 hypomethylated CpG
sites comparing SCC to AC. Methylation values are represented as
row Z-scores for each gene. Red indicates high methylation and
blue indicates low methylation relative to the row mean.
(PDF)
Figure S3 Scatterplots showing the correlation between
beta values determined by Illumina methylation arrays
and Sanger bisulfite sequencing. Shown are the best-fitting
line, Pearson’s correlation coefficient and p-value of correlation
tests. The mean correlation between two methods was 83% (range
48.9%; 97.4%).
(DOC)
Figure S4 Scatterplots showing the correlation between
Illumina microarray and qRT-PCR measurements. On
the x-axis is quantile-normalized and logarithmic fold change
(log2TU-log2N) on the microarray for eight sample pairs. On the
y-axis is DDCt value for same sample pairs. Shown are the best-
fitting line, Pearson’s correlation coefficient and correlation test p-
value.
(TIFF)
Figure S5 TNF network. The in silico functional and in-
teraction analysis of differently methylated genes was performed
using the Ingenuity Pathway Analysis (IPA) software. The most
prominently represented gene network was related to tumor
necrosis factor. The genes that were hypermethylated in NSCLC
are shown with a red background, and the genes that were
hypomethylated in NSCLC are shown with a green background.
The depicted interactions are mostly indirect.
(TIF)
Figure S6 Boxplots of differentially methylated CpGs in
different survival groups. The 18 CpGs in 15 genes had
statistically different methylation (p-value ,0.05, Beta-value
#0.136) between patients with 1 to 24 months survival (n=12)
vs patients with 60 months and longer survival (n=15).
Methylation values are also shown for patients with 25–59 months
survival and for normal lung tissue.
(PDF)
Table S1 Differentially methylated CpGs and genes in
stage I NSCLC compared to cancer-free lung control
samples. Mean Beta represents the methylated signals divided by
the sum of methylated and unmethylated signals for each analyzed
CpG. Beta-diff. was calculated by subtracting the Mean Beta value
of a cancer-free lung from the Mean Beta value of stage I NSCLC
samples.
(XLS)
Table 2. Statistically significant Pearson’s correlations
between differentially methylated CpG sites and gene
expression values across 48 lung cancer samples and the
control samples with available gene expression data.
Symbol Gene ID Pearson R
Permuted p-
value*
AGER 177 20.8095317 0.0143
BRDT 676 20.7664438 0.0477
CALML5 51806 20.7729556 0.0419
ELAVL4 1996 20.8363362 0.0027
GSTT1 2952 20.7698949 0.0450
MAGEC1 9947 20.7886890 0.0278
MB 4151 20.7765738 0.0390
NR0B2 8431 20.8705916 0.0002
P53AIP1 63970 20.7665071 0.0477
PNLDC1 154197 20.8677312 0.0002
PPP1R14D 54866 20.8137714 0.0121
P-values were computed by permuting individuals and recalculating the
median gene expression levels 1,000 times. All CpGs and genes represented by
both methylation and gene expression arrays were included in permutations.
*- Permuted p-value - p-value computed by permuting individuals and
recalculating the median gene expression levels 1,000 times.
doi:10.1371/journal.pone.0039813.t002
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39813Table S2 Differentially methylated CpGs and genes in
squamous cell carcinoma (SCC) compared to adenocar-
cinoma (AC) samples. Mean Beta represents the methylated
signals divided by the sum of methylated and unmethylated signals
for each analyzed CpG. Beta-diff. was calculated by subtracting
the Mean Beta value of AC from the Mean Beta value of SCC.
(XLS)
Table S3 A detailed overview of the patient cohort
involved in our study.
(DOC)
Table S4 PCR primers used in methylation validation
with Sanger sequencing.
(DOC)
Table S5 Quantitative real-time PCR primers used for
TP73 gene isoform analysis.
(DOC)
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